This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

  • Clinicaltrials.gov identifier

    NCT04350463

  • Recruitment Status

    Recruiting

  • First Posted

    April 17, 2020

  • Last update posted

    July 13, 2021

Study Description

Brief summary:

This is a Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with small cell lung cancer or squamous non-small cell lung cancer who have progressed after 1 or 2 lines of therapies. The primary objectives of the study are to evaluate the overall response rate of subjects treated with CC-90011 in combination with nivolumab in three cohorts: - Cohort A: SCLC in ICI naïve subjects - Cohort B: SCLC in ICI progressor subjects - Cohort C: sqNSCLC in ICI progressor subjects Overall response rate is defined as the proportion of subjects in the treated population who had complete response (CR) or partial response (PR) as assessed by Investigator review per RECIST v1.1. In Cohort A, expected ORR for nivolumab monotherapy is 14% while target ORR is 30%. To achieve at least 80% power with one-sided type 1 error 0.1, 39 subjects will be enrolled according to a 2-stage group sequential design based on a binomial test. In stage 1, 12 subjects will be enrolled and treated with CC-90011 in combination with nivolumab. If there are 2 or more subjects responding, Cohort A will continue to enroll an additional 27 subjects. If 1 or less subjects respond in stage 1, Cohort A will stop for futility. In Cohort B and C, expected ORR for nivolumab monotherapy is 5% while target ORR is 15%. To achieve at least 80% power with one-sided type 1 error 0.1, 48 subjects will be enrolled according to a 2-stage group sequential design based on a binomial test. In stage 1, 14 subjects will be enrolled and treated with CC-90011 in combination with nivolumab. If there are 1 or more subjects responding, Cohort B and C will continue to enroll an additional 34 subjects each. If 0 subjects respond in stage 1, Cohort B and C will stop for futility.

  • Condition or Disease:Neoplasms
  • Intervention/Treatment: Drug: CC-90011
    Drug: Nivolumab
  • Phase: Phase 2

Detailed Description

N/A

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 135 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 2, Multicenter, Open-label, Multi-cohort Study to Assess Safety and Efficacy of CC-90011 in Combination With Checkpoint Inhibitor(s) in Subjects With Advanced Cancers
  • Actual Study Start Date: July 2020
  • Estimated Primary Completion Date: December 2022
  • Estimated Study Completion Date: September 2024

Arms and interventions

Arm Intervention/treatment
Experimental: Arm A: SCLC in ICI naïve subjects
CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle. Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice.
Drug: CC-90011
CC-90011

Drug: Nivolumab
Nivolumab
Experimental: Cohort B: SCLC in ICI progressor subjects
CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle. Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice.
Drug: CC-90011
CC-90011

Drug: Nivolumab
Nivolumab
Experimental: Cohort C: sqNSCLC in ICI progressor subjects
CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle. Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice.
Drug: CC-90011
CC-90011

Drug: Nivolumab
Nivolumab

Outcome Measures

  • Primary Outcome Measures: 1. Overall response rate [ Time Frame: Up to 24 months ]
    The proportion of subjects in the treated population who had complete response (CR) or partial response (PR) as assessed by Investigator review per RECIST v1.1
  • Secondary Outcome Measures: 1. Adverse Events (AEs) [ Time Frame: Up to 24 months ]
    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. All adverse events will be collected and collated according to grade and frequency. This will include all events considered related or unrelated to study therapy.
  • 2. Duration of response [ Time Frame: Up to 24 months ]
    Every 6 weeks post C1D1 for the first 24 weeks and then every 8 weeks until disease progression, new anticancer therapy, death or withdrawal by subject.
  • 3. Progression-free survival [ Time Frame: Up to 24 months ]
    The time from the first dose of the study drug to the date of the first objectively documented tumor progression as assessed by Investigator review per RECIST v1.1 or death from any cause, whichever occurs first.
  • 4. Overall Survival [ Time Frame: Up to 48 months ]
    The time from the first dose of the study drug to the date of death due to any cause.
  • 5. Time to Response [ Time Frame: Up to 24 months ]
    The time from the first dose of the study drug to the date of the first confirmed documented response (CR or PR), as assessed by Investigator review per RECIST v1.1.
  • 6. Time to first subsequent therapy [ Time Frame: Up to 48 months ]
    The time from the first dose of the study drug to the date of the next cancer therapy or death.

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: 1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Subject with histological or cytological confirmation of extensive stage Small Cell Lung Cancer (ES SCLC) or Stage IIIb or IV squamous Non-Small Cell Lung Cancer (sqNSCLC) 3. Subject has received 1 or 2 prior lines of therapies, defined as: 1. Cohort A (SCLC, Immune Checkpoint Inhibitor naïve): - At least 1 prior treatment including a platinum-based chemotherapy doublet - A minimum of 3 cycles of platinum-based chemotherapy in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity 2. Cohort B (SCLC, ICI progressors): - At least 1 prior first or second line treatment includes an ICI - If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed - At least 1 prior treatment including a platinum-based chemotherapy doublet - A minimum of 3 cycles of platinum-based chemotherapy, with or without ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity - Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy) 3. Cohort C (sqNSCLC, ICI progressors): - At least 1 prior first or second line treatment includes an ICI - If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed - At least 1 prior treatment including a platinum-based chemotherapy doublet - A minimum of 3 cycles of platinum-based chemotherapy, with or without an ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity - Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy) 4. Subject has progressed at the last line of therapy. 5. Subject has a measurable disease defined by RECIST v1.1. 6. Subject agrees to provide a tumor biopsy from primary or metastatic site prior to first dose and at a pre-specified timepoint during treatment. Core biopsy is required however, in the event a core biopsy may not otherwise be feasible in the opinion of the treating physician, an endobronchial ultrasound-guided fine needle aspirate [EBUS-FNA]) biopsy, using the largest gauge needle, may be performed instead. 7. Subject has ECOG Performance Status of 0 to 1. 8. Subject must have the following laboratory values: 1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L 2. Hemoglobin (Hgb) ≥ 9 g/dL (one-time blood transfusion is allowed) 3. Platelet (Plt) Count ≥ 150 x 109/L 4. White blood cells (WBC) ≥ 2 x 109L 5. Serum AST/serum glutamic oxaloacetic transaminase (SGOT) or ALT/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x upper limit of normal (ULN) or ≤ 5 x ULN if presence of liver metastases 6. Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN, if Gilbert's syndrome or if indirect bilirubin concentrations are suggestive of extrahepatic source of the elevation) 7. Creatinine clearance (CrCl) ≥ 60 mL/minute based on Cockcroft-Gault or modification of diet in renal disease (MDRD) or ≥ 60 mL/min/1.73 m2 Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: 1. Subject has not recovered to Grade 2 or lower clinically significant toxicities related to the prior therapy (alopecia excluded). 2. Subject has received prior LSD1 therapies. 3. Subject has a history of severe hypersensitivity reactions to other monoclonal antibodies 4. Subject with symptomatic and untreated or unstable central nervous system (CNS) metastases. 1. Subject has recently been treated with whole brain radiation or stereotactic radiosurgery for CNS metastases must have completed therapy at least 2 weeks prior to Cycle 1 Day 1 and has a follow-up brain computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating either stable or improving metastases 2 or more weeks after completion of radiotherapy. 2. Subject must be asymptomatic and off steroids or on stable dose of steroids for at least 2 weeks (≤ 10 mg daily prednisone or equivalent) prior to first dose. 5. Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or any other significant gastrointestinal (GI) disorder that could affect the absorption of the study treatments. 6. Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and GI tract hemorrhages. 7. Subject with any hemorrhage/bleeding event > NCI CTCAE Grade 2 or haemoptysis > 1 teaspoon within 4 weeks prior to the first dose. 8. Subject has any of the following cardiovascular criteria: 1. Evidence of acute or ongoing cardiac ischemia 2. Current symptomatic pulmonary embolism 3. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to enrollment 4. Heart failure of New York Heart Association Classification III or IV ≤ 6 months prior to enrollment 5. Persistent or clinically meaningful ventricular arrhythmias prior to enrollment 6. Cerebral vascular accident or transient ischemic attack ≤ 6 months prior to enrollment 7. QT corrected based on Fridericia's equation (QTcF) ≥ 450 milliseconds (msec) on Screening ECG, a baseline prolongation of QTcF interval ≥ 450 msec (NCI CTCAE Grade ≥ 2) 8. A history of additional risk factors for Torsades de pointes (TdP) (eg, heart failure, hypokalemia, family history of Long QT Syndrome) 9. Uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg) 9. Subject has known human immunodeficiency virus (HIV) infection. 10. Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection. 1. Subject who is seropositive due to HBV vaccination is eligible. 2. Subject who has no active viral infection and is under adequate prophylaxis against HBV reactivation is eligible. 11. Subject has any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, nonmelanomatous skin cancer, ductal in situ breast carcinoma, thyroid cancer, or early stage prostate cancer (all treatment of which should have been completed 6 months prior to enrollment). 12. Subject has medical conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. 1. A brief (≤ 7 days) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted. 2. Adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease. 3. Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted. 13. Subject has active autoimmune diseases or history of autoimmune diseases that may relapse. Subjects with the following diseases are allowed to be enrolled after further screening: type I diabetes, hypothyroidism managed with hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia), or diseases not expected to recur in the absence of external triggering factors. 14. Subject is pregnant or nursing. 15. Subject has a history of persistent skin rash ≥ NCI CTCAE Grade 2 related to prior ICI therapy. 16. Subject has organ transplant history, including allogeneic stem cell transplant. 17. Subject has interstitial lung disease history. 18. Subject has received a live/attenuated vaccine within 30 days of first dose. 19. Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening. 1. Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment.

Contacts and Locations

Contacts

Contact: Associate Director, Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations

France
Hospital Pontchaillou
Rennes

France
Hopital Louis Pradel
Lyon Cedex

France
Hospital Le Timone
Marseille Cedex 5

France
CHU Nantes Hopital Nord Laennec
Saint-Herblain

France
Gustave Roussy
Villejuif CEDEX

United States, Georgia
Augusta University - Georgia Cancer Center
Augusta

United States, Indiana
Investigative Clinical Research of Indiana, LLC
Indianapolis

United States, New York
Memorial Sloan-Kettering Cancer Center - David H. Koch Center for Cancer Care
New York

United States, North Carolina
Novant Health Presbyterian Medical Center
Charlotte

United States, North Carolina
Piedmont Hematology Oncology Associates
Winston-Salem

United States, Ohio
Gabrail Cancer Center Research
Canton

United States, Ohio
University Hospitals Cleveland Medical Center
Cleveland

United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh

United States, Texas
Brooke Army Medical Center Francis Street Medical Center
Fort Sam Houston

United States, Texas
Millennium Oncology
Houston

United States, Virginia
Virginia Cancer Specialists, PC
Fairfax

Italy
Centro di Riferimento Oncologico
Aviano

Italy
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.)
Meldola

Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan

Italy
Policlinico Universitario Campus Biomedico Di Roma
Roma

Italy
Azienda Ospedaliera Universitaria Integrata di Verona
Verona

Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz

Poland
Instytut Centrum Zdrowia Matki Polki
Lodz

Poland
Med Polonia Sp. z o.o. NSZOZ
Poznan

Poland
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw

Spain
Hospital Universitari Germans Trias i Pujol Can Ruti
Badalona (Barcelona)

Spain
Hospital Quiron Barcelona
Barcelona

Spain
Hospital Universitari Vall d'Hebron
Barcelona

Spain
Complejo Universitario La Coruna
La Coruna

Spain
Insular-Maternal and Child University Hospital Complex
Las Palmas de Gran Canaria

Spain
Clinica Universidad de Navarra
Madrid

Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid

Spain
Hospital Universitario 12 de Octubre
Madrid

Spain
Hospital Puerta de Hierro
Majadahonda, Madrid

Spain
Clinica Universidad de Navarra
Pamplona

Spain
Hospital General de Valencia
Valencia

Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia

United Kingdom
Clatterbridge Centre for Oncology NHS Trust
Bebington, Wirral

United Kingdom
The Royal Marsden Hospital
London

United Kingdom
The Christie NHS Foundation Trust
Manchester

United Kingdom
Royal Marsden Hospital
Sutton-Surrey

Sponsors and Collaborators

Celgene

Investigators

Study Director: Ileana Elias, Medical Director Celgene

More Information

  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT04350463 History of Changes
  • Other Study ID Numbers: CC-90011-ST-002, U1111-1248-8352, 2019-004194-95
  • First Posted: April 17, 2020 Key Record Dates
  • Last Update Posted: July 13, 2021
  • Last Verified: July 2021
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: LSD1 inhibitor
    Squamous non-small cell lung cancer
    Small cell lung cancer
    Advanced Cancers
    Nivolumab
    CC-90011